Agreement - August 9, 2022
Recipharm and Transpire Bio enter agreement
The development-stage pharmaceutical company Transpire Bio has announced a definitive agreement with Recipharm to develop TRB-1 and TRB-2, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). TRB-1 and TRB-2, the first products developed by Transpire Bio will be indicated for the treatment of asthma and COPD, intended for advanced markets. […]
Agreement - July 1, 2022
Scandinavian Biopharma enters marketing and distribution agreement
Scandinavian Biopharma has expanded the partnership with Emergent Travel Health Inc. to also include the marketing and distribution of Emergent’s oral typhoid vaccine (Ty21a) in Germany. Emergents oral typhoid vaccine will complement and strengthen Scandinavian Biopharma’s commercial portfolio by leveraging its existing marketing and distribution network in Germany, it states. Due to the travel restrictions […]
Agreement - June 23, 2022
Novo Nordisk and Echosens enter partnership
The two companies have announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders. Echosens and Novo Nordisk will collaborate to support additional clinical validation, generation of real-world evidence and adoption of non-invasive diagnostic tests for NASH and work together to […]
Agreement - June 16, 2022
BioInvent and Exelixis establish exclusive agreement
The two companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics. The collaboration is intended to expand Exelixis’ portfolio of antibody-based therapies and will combine BioInvent’s cancer immunology and antibody biology expertise with Exelixis’ expertise and resources in antibody engineering and […]
Agreement - June 13, 2022
Bavarian Nordic enters multi-year vaccine contract
The Public Health Agency of Canada (PHAC) will be purchasing IMVAMUNE smallpox vaccine at a value of approximately USD 56 million. The non-replicating smallpox vaccine is also approved for use against monkeypox in Canada as the only territory other than the USA. Deliveries of vaccines under this five-year contract are expected to occur from 2023. […]
Agreement - June 1, 2022
Immedica enters agreement with OrphanPacific
Immedica Pharma and Japanese company OrphanPacific entered an agreement under which OrphanPacific gains the exclusive rights to Ravicti in Japan. The pharmaceutical drug product Ravicti is approved in Europe and North America for treatment of urea cycle disorders (UCD). Under the announced partnership, OrphanPacific is granted a license to develop, register and commercialize the product […]
